Drugs & Therapy Perspectives

, Volume 34, Issue 10, pp 466–471 | Cite as

Consider using biological agents or stem cell therapy when managing perianal Crohn’s disease

  • Adis Medical WritersEmail author
Disease Management


Perianal Crohn’s disease is associated with significant morbidity, impaired health-related quality-of-life and high healthcare costs. Treatment differs according to the type and severity of the fistula, and a multidisciplinary approach is recommended. Patients with complex perianal fistulas who do not respond to first-line therapy with tumour necrosis factor inhibitors (± immunomodulators) may benefit from new biological agents, such as vedolizumab and ustekinumab, or the local application of mesenchymal stem cells.


Compliance with ethical standards

Conflict of interest

The article was adapted from Drugs 2018;78(1):1–18 [2] by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.


The preparation of this review was not supported by any external funding.


  1. 1.
    Kelley KA, Kaur T, Tsikitis VL. Perianal Crohn’s disease: challenges and solutions. Clin Exp Gastroenterol. 2017;10:39–46.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Bermejo F, Guerra I, Algaba A, et al. Pharmacological approach to the management of Crohn’s disease patients with perianal disease. Drugs. 2018;78(1):1–18.PubMedCrossRefGoogle Scholar
  3. 3.
    Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg. 1976;63(1):1–12.CrossRefGoogle Scholar
  4. 4.
    Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125(5):1508–30.PubMedCrossRefGoogle Scholar
  5. 5.
    Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63(9):1381–92.PubMedCrossRefGoogle Scholar
  6. 6.
    Hong MK, Craig Lynch A, Bell S, et al. Faecal diversion in the management of perianal Crohn’s disease. Colorectal Dis. 2011;13(2):171–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohn’s Colitis. 2017;11(2):135–49.CrossRefGoogle Scholar
  8. 8.
    Turunen UM, Farkkila MA, Hakala K, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology. 1998;115(5):1072–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009;15(1):17–24.PubMedCrossRefGoogle Scholar
  10. 10.
    Solomon MJMR, Oconnor BI. Combination ciprofloxacin and metronidazole in severe perianal. Crohns Dis. 1993;7:571–3.Google Scholar
  11. 11.
    Brandt LJ, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology. 1982;83(2):383–7.PubMedGoogle Scholar
  12. 12.
    Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn’s disease with metronidazole. Gastroenterology. 1980;79(3):599.PubMedGoogle Scholar
  13. 13.
    Jakobovits J, Schuster MM. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol. 1984;79(7):533–40.PubMedGoogle Scholar
  14. 14.
    Maeda Y, Ng SC, Durdey P, et al. Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn’s disease. Br J Surg. 2010;97(9):1340–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Cat H, Sophani I, Lemann M, et al. Cyclosporin treatment of anal and perianal lesions associated with Crohn’s disease. Turk J Gastroenterol. 2003;14(2):121–7.PubMedGoogle Scholar
  16. 16.
    Hanauer SB, Smith MB. Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol. 1993;88(5):646–9.PubMedGoogle Scholar
  17. 17.
    Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn’s disease. Dig Dis Sci. 1994;39(2):374–80.PubMedCrossRefGoogle Scholar
  18. 18.
    Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology. 2003;125(2):380–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn’s disease: exploratory randomized controlled trial. Inflamm Bowel Dis. 2007;13(3):245–53.PubMedCrossRefGoogle Scholar
  20. 20.
    Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123(2):132–42.PubMedCrossRefGoogle Scholar
  21. 21.
    Kariyawasam VC, Selinger CP, Katelaris PH, et al. Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn’s disease. Inflamm Bowel Dis. 2014;20(8):1382–90.PubMedCrossRefGoogle Scholar
  22. 22.
    Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology. 2013;145(4):758–65.e2.Google Scholar
  23. 23.
    Dejaco C, Harrer M, Waldhoer T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Ther. 2003;18(11–12):1113–20.PubMedCrossRefGoogle Scholar
  24. 24.
    Yarur AJ, Kubiliun MJ, Czul F, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015;13(6):1118–24.e3.Google Scholar
  25. 25.
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398–405.PubMedCrossRefGoogle Scholar
  26. 26.
    Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology. 2005;128(4):862–9.PubMedCrossRefGoogle Scholar
  27. 27.
    West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20(11–12):1329–36.PubMedCrossRefGoogle Scholar
  28. 28.
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.PubMedCrossRefGoogle Scholar
  29. 29.
    Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut. 2009;58(7):940–8.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Panaccione R, Loftus EV Jr, Binion D, et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn’s disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) trial. Can J Gastroenterol. 2011;25(8):419–25.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32(10):1228–39.PubMedCrossRefGoogle Scholar
  32. 32.
    Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63(2):292–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357(3):239–50.PubMedCrossRefGoogle Scholar
  34. 34.
    Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357(3):228–38.PubMedCrossRefGoogle Scholar
  35. 35.
    Schreiber S, Lawrance IC, Thomsen OO, et al. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease—subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011;33(2):185–93.PubMedCrossRefGoogle Scholar
  36. 36.
    Yang C, Singh P, Singh H, et al. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(11):1079–93.PubMedCrossRefGoogle Scholar
  37. 37.
    Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003;9(2):98–103.PubMedCrossRefGoogle Scholar
  38. 38.
    Gaertner WB, Decanini A, Mellgren A, et al. Does infliximab infusion impact results of operative treatment for Crohn’s perianal fistulas? Dis Colon Rectum. 2007;50(11):1754–60.PubMedCrossRefGoogle Scholar
  39. 39.
    Feagan B, Schwartz D, Danese S, et al. Vedolizumab for the treatment of fistulizing Crohn’s disease: an exploratory analysis of data from GEMINI 2. J Crohn’s Collitis. 2015;9(Suppl 1):S333.Google Scholar
  40. 40.
    Tadbiri S, Grimaud J, Peyrin-Biroulet L, et al. Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a posthoc analysis of the OBSERV-IBD cohort from the GETAID. J Crohn’s Collitis. 2017;11(Suppl 1):S42.CrossRefGoogle Scholar
  41. 41.
    Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease–the McGill experience. J Crohn’s Colitis. 2014;8(11):1516–22.CrossRefGoogle Scholar
  42. 42.
    Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to antitumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(2):242–50.e1–2.Google Scholar
  43. 43.
    Khorrami S, Ginard D, Marin-Jimenez I, et al. Ustekinumab for the treatment of refractory Crohn’s disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22(7):1662–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Sands B, Gasink C, Jacobstein D, et al. Fistula healing in pivotal studies of ustekinumab in Crohn’s disease. Gastroenterology. 2017;152(5):S185.CrossRefGoogle Scholar
  45. 45.
    Ma C, Fedorak RN, Kaplan GG, et al. Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn’s disease: real-world experience from a multicenter cohort study. Inflamm Bowel Dis. 2017;23(5):833–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Battat R, Kopylov U, Bessissow T, et al. Association among ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017;15(9):1427–34.PubMedCrossRefGoogle Scholar
  47. 47.
    Garcia-Olmo D, Garcia-Arranz M, Herreros D, et al. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48(7):1416–23.PubMedCrossRefGoogle Scholar
  48. 48.
    Cho YB, Lee WY, Park KJ, et al. Autologous adipose tissue-derived stem cells for the treatment of Crohn’s fistula: a phase I clinical study. Cell Transplant. 2013;22(2):279–85.PubMedCrossRefGoogle Scholar
  49. 49.
    Lee WY, Park KJ, Cho YB, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn’s fistula. Stem Cells. 2013;31(11):2575–81.PubMedCrossRefGoogle Scholar
  50. 50.
    Choi S, Ryoo SB, Park KJ, et al. Autologous adipose tissue-derived stem cells for the treatment of complex perianal fistulas not associated with Crohn’s disease: a phase II clinical trial for safety and efficacy. Tech Coloproctol. 2017;21(5):345–53.PubMedCrossRefGoogle Scholar
  51. 51.
    Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52(1):79–86.PubMedCrossRefGoogle Scholar
  52. 52.
    Dietz AB, Dozois EJ, Fletcher JG, Butler GW, Radel D, Lightner AL, et al. Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2017;153(1):59–62.e2.Google Scholar
  53. 53.
    Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut. 2011;60(6):788–98.PubMedCrossRefGoogle Scholar
  54. 54.
    de la Portilla F, Alba F, Garcia-Olmo D, et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013;28(3):313–23.PubMedCrossRefGoogle Scholar
  55. 55.
    Park KJ, Ryoo SB, Kim JS, Kim TI, Baik SH, Kim HJ, et al. Allogeneic adipose-derived stem cells for the treatment of perianal fistula in Crohn’s disease: a pilot clinical trial. Colorectal Dis. 2016;18(5):468–76.PubMedCrossRefGoogle Scholar
  56. 56.
    Panes J, Garcia-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281–90.PubMedCrossRefGoogle Scholar
  57. 57.
    Molendijk I, Bonsing BA, Roelofs H, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2015;149(4):918–27.e6.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations